CTSS and ovarian carcinoma: In contrast, bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism in ER+ breast and ovarian cancer cells (Periyasamy-Thandavan et al., 2010; Kao et al., 2014).